Aigen Investment Management, LP Macrogenics Inc Transaction History

Aigen Investment Management, LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$9.77 - $21.47 $226,634 - $498,039	23,197 New	23,197 $341,000
Q4 2020 Feb 12, 2021	SELL	$19.41 - $26.0 $360,482 - $482,872	-18,572 Closed	0 $0
Q3 2020 Nov 06, 2020	SELL	$24.69 - $31.6 $143,646 - $183,848	-5,818 Reduced 23.85%	18,572 $468,000
Q2 2020 Aug 10, 2020	BUY	$5.2 - $29.12 $126,828 - $710,236	24,390 New	24,390 $681,000

132

55.4M

215K

238K

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $200M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

Get notified when there are updates to the investment portfolio of Aigen Investment Management, LP, based on Form 13F filings with the SEC.

Stay updated on Aigen Investment Management, LP with notifications on news.